Other observations revealed that a systemic application of CD11b blocking antibodies after radiation increased anti-tumor immune responses, which has been explained by a reduced myeloid cell migration to the tumor site and an attenuated support of tumor neovascularization [230]. The gene discussed is ITGAM; the disease is neoplasm.